Log in

NASDAQ:ACHVAchieve Life Sciences Stock Price, Forecast & News

$11.13
+0.14 (+1.27 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.75
Now: $11.13
$11.42
50-Day Range
$7.76
MA: $9.48
$13.94
52-Week Range
$4.51
Now: $11.13
$50.20
Volume294,704 shs
Average Volume231,977 shs
Market Capitalization$17.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Read More
Achieve Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHV
CUSIP68230A10
Phone604-210-2217

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$12.24 per share

Profitability

Net Income$-16,400,000.00

Miscellaneous

Employees13
Market Cap$17.45 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$11.13
+0.14 (+1.27 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

How has Achieve Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Achieve Life Sciences' stock was trading at $8.3240 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACHV shares have increased by 33.7% and is now trading at $11.13.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Achieve Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Achieve Life Sciences
.

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Achieve Life Sciences
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences Inc (NASDAQ:ACHV) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($3.80) by $2.12.
View Achieve Life Sciences' earnings history
.

When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?

Achieve Life Sciences's stock reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ACHV?

3 analysts have issued twelve-month price objectives for Achieve Life Sciences' stock. Their forecasts range from $40.00 to $100.00. On average, they anticipate Achieve Life Sciences' share price to reach $60.00 in the next twelve months. This suggests a possible upside of 439.1% from the stock's current price.
View analysts' price targets for Achieve Life Sciences
.

Has Achieve Life Sciences been receiving favorable news coverage?

Media headlines about ACHV stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Achieve Life Sciences earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Achieve Life Sciences
.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 381,800 shares, a decrease of 81.1% from the December 15th total of 2,020,000 shares. Based on an average trading volume of 1,560,000 shares, the days-to-cover ratio is currently 0.2 days.
View Achieve Life Sciences' Short Interest
.

Who are some of Achieve Life Sciences' key competitors?

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), AEterna Zentaris (AEZS), ADMA Biologics (ADMA), Novan (NOVN), BioNano Genomics (BNGO), Zosano Pharma (ZSAN) and Cannabics Pharmaceuticals (CNBX).

Who are Achieve Life Sciences' key executives?

Achieve Life Sciences' management team includes the following people:
  • Dr. Richard A. B. Stewart, Chairman & CEO (Age 60)
  • Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 63)
  • Mr. John A. Bencich, Exec. VP, CFO & COO (Age 42)
  • Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 61)
  • Ms. Jaime Xinos, Exec. VP of Commercial

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.29%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart.
View institutional ownership trends for Achieve Life Sciences
.

Which institutional investors are buying Achieve Life Sciences stock?

ACHV stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund, and Richard Alistair Stewart.
View insider buying and selling activity for Achieve Life Sciences
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $11.13.

How big of a company is Achieve Life Sciences?

Achieve Life Sciences has a market capitalization of $17.45 million. The biopharmaceutical company earns $-16,400,000.00 in net income (profit) each year or ($39.80) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.

What is Achieve Life Sciences' official website?

The official website for Achieve Life Sciences is achievelifesciences.com.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.